MIB relies on a powerful multidisciplinary network of public, economic, private and academic partners.
This network, which is MIB’s real strength, enables us to benefit from a multitude of skills, resources and expertise.
Thanks to the diversity and complementarity of its founders, MIB is positioned as a scientific and economic center of excellence on an international scale.
President of SATT Sud-Est
Delegate vice-president, A*Midex
Coordinator France 2030
Chairman of the Management
Board Executive Vice President
Chairman of the CCI
Director, Inserm Research at Brest University Hospital
General Manager, AP-HM
Director of Partnerships,
Laboratoires Servier
CEO, ImCheck Therapeutics
Director of Health Research and Rare Diseases, AP-HM
CEO, MIB
Representative, Métropole
Aix-Marseille
Project Scientific and
Technical Manager, MIB
CEO, CNRS
Administrative manage, MIB
Director of Research and Innovation, Institution National du Cancer
Scientific Operations Manager,
MIB
General Manager, Eurobiomed
General Manager, OFU
General Manager,
Institut Paoli-Calmettes
President of SATT
Sud-Est
Delegate Vice-President A*Midex France 2030 Coordinator
Chairman of the Executive Board
Chief Operating Officer by intermediary
Chairman of the CCI
Inserm Research Director at Brest University Hospital
General Manager of APHM
Director of Partnerships, Laboratoires Servier
CEO ImCheck Therapeutics
Director of Health Research and Rare Diseases at AP-HM
Representative of Métropole Aix-Marseille
MIB Project Scientific and Technical Manager
CEO, CNRS
Director of Research and Innovation, French National Cancer Institute
Scientific Operations Manager
Managing Director, Eurobiomed
OFU General Manager
Managing Director, Institut Paoli-Calmettes
The launch of the Marseille Immunology Biocluster (MIB)’s Scientific Advisory Board (SAB) marks a major milestone in the Biocluster’s journey. As President of this independent body, I am honored to join a panel of other globally respected experts spanning a wide spectrum of immunology research. Our mission to critically and independently assess the scientific merit of MIB’s research programs is not merely a responsibility, but a vital condition for credible, high-impact innovation. Scientific excellence thrives on constant challenge, fresh perspectives, and unwavering integrity, both from outside and from within. MIB has set itself a bold 10-year vision: to deliver a new generation of antibody-based therapies, including a blockbuster drug. The work ahead is substantial. But with clear purpose and uncompromising standards, such a goal is within reach. The importance of this endeavor cannot be overstated. Immunology sits at the crossroads of some of the most pressing health challenges of our time. It offers insights and, often, transformative solutions to major health needs such as cancer, infection, chronic inflammation, and autoimmune conditions. By investing in this field, and by holding its research to the highest standards, MIB is helping to drive progress that will be felt far beyond its borders. Our mission at the SAB is to accompany this effort with objectivity, critical insight, and a deep belief in the power of science. Together, with researchers, entrepreneurs, public stakeholders, and the broader community, we can turn today’s ideas into tomorrow’s therapies.
Pedro Romero President of the Scientific Advisory Board, Marseille Immunology Biocluster